Empagliflozin decreases ageing-associated arterial stiffnening and decreases vascular fibrosis under normoglycemic conditions
In conclusion, empagliflozin decreased arterial stiffness in aged mice, indicating that SGLT2 inhibition could be a valuable strategy in mitigating vascular ageing. Further research is warranted to unravel the underlying, possibly region-specific, mechanisms.PMID:37619798 | DOI:10.1016/j.vph.2023.107212 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 24, 2023 Category: Drugs & Pharmacology Authors: C édric H G Neutel Callan D Wesley Melissa Van Praet Celine Civati Lynn Roth Guido R Y De Meyer Wim Martinet Pieter-Jan Guns Source Type: research
Empagliflozin decreases ageing-associated arterial stiffnening and decreases vascular fibrosis under normoglycemic conditions
In conclusion, empagliflozin decreased arterial stiffness in aged mice, indicating that SGLT2 inhibition could be a valuable strategy in mitigating vascular ageing. Further research is warranted to unravel the underlying, possibly region-specific, mechanisms.PMID:37619798 | DOI:10.1016/j.vph.2023.107212 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 24, 2023 Category: Drugs & Pharmacology Authors: C édric H G Neutel Callan D Wesley Melissa Van Praet Celine Civati Lynn Roth Guido R Y De Meyer Wim Martinet Pieter-Jan Guns Source Type: research
Exploring the significance of epicardial adipose tissue in aortic valve stenosis and left ventricular remodeling: Unveiling novel therapeutic and prognostic markers of disease
Vascul Pharmacol. 2023 Aug 21:107210. doi: 10.1016/j.vph.2023.107210. Online ahead of print.ABSTRACTAortic stenosis (AS) is a dynamic degenerative process that shares many pathophysiological features with atherogenesis, from initial proinflammatory calcification and focal thickening of the valve leaflets to obstruction of left ventricular outflow due to superimposed of severe calcification and immobilization of the valve leaflets. As the prevalence increases with age, AS is expected to become one of the most common heart diseases worldwide. In both obese and nonobese patients, persistent thickening of epicardial adipose ti...
Source: Vascular Pharmacology - August 23, 2023 Category: Drugs & Pharmacology Authors: Stefano Quarta Giuseppe Santarpino Maria Annunziata Carluccio Nadia Calabriso Michele Maffia Luisa Siculella Fabrizio Damiano Rosalinda Madonna Marika Massaro Source Type: research
Exploring the significance of epicardial adipose tissue in aortic valve stenosis and left ventricular remodeling: Unveiling novel therapeutic and prognostic markers of disease
Vascul Pharmacol. 2023 Aug 21:107210. doi: 10.1016/j.vph.2023.107210. Online ahead of print.ABSTRACTAortic stenosis (AS) is a dynamic degenerative process that shares many pathophysiological features with atherogenesis, from initial proinflammatory calcification and focal thickening of the valve leaflets to obstruction of left ventricular outflow due to superimposed of severe calcification and immobilization of the valve leaflets. As the prevalence increases with age, AS is expected to become one of the most common heart diseases worldwide. In both obese and nonobese patients, persistent thickening of epicardial adipose ti...
Source: Vascular Pharmacology - August 23, 2023 Category: Drugs & Pharmacology Authors: Stefano Quarta Giuseppe Santarpino Maria Annunziata Carluccio Nadia Calabriso Michele Maffia Luisa Siculella Fabrizio Damiano Rosalinda Madonna Marika Massaro Source Type: research
Type I collagen proteolysis by matrix metalloproteinase-2 contributes to focal adhesion kinase activation and vascular smooth muscle cell proliferation in the aorta in early hypertension
CONCLUSIONS: Increase in MMP-2 activity proteolyzes type I collagen in the aortas of 2K1C rats and contributes to activate FAK and induces VSMC proliferation during the initial phase of hypertension.PMID:37607602 | DOI:10.1016/j.vph.2023.107211 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 22, 2023 Category: Drugs & Pharmacology Authors: Viviano Gomes de Oliveira Neves Marcela M Blascke de Mello Daniel Rodrigues Laena Pernomian Isadora Sousa de Oliveira Juliana M Parente Eliane Candiani Arantes Rita Tostes Michele M Castro Source Type: research
The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: A narrative review
Vascul Pharmacol. 2023 Aug 15;152:107209. doi: 10.1016/j.vph.2023.107209. Online ahead of print.ABSTRACTVascular endothelial and smooth muscle cell dysfunction proceed the development of numerous vascular diseases, such as atherosclerosis. Both estrogen and progesterone receptors are present on vascular endothelial and smooth muscle cells, and therefore it has been postulated that these compounds may affect vascular function. It has been well-established that estrogen is a vasoprotective compound, however, the effects of progesterone on vascular function are not well understood. This narrative review summarizes the current...
Source: Vascular Pharmacology - August 17, 2023 Category: Drugs & Pharmacology Authors: Jenna C Stone Maureen J MacDonald Source Type: research
The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: A narrative review
Vascul Pharmacol. 2023 Aug 15;152:107209. doi: 10.1016/j.vph.2023.107209. Online ahead of print.ABSTRACTVascular endothelial and smooth muscle cell dysfunction proceed the development of numerous vascular diseases, such as atherosclerosis. Both estrogen and progesterone receptors are present on vascular endothelial and smooth muscle cells, and therefore it has been postulated that these compounds may affect vascular function. It has been well-established that estrogen is a vasoprotective compound, however, the effects of progesterone on vascular function are not well understood. This narrative review summarizes the current...
Source: Vascular Pharmacology - August 17, 2023 Category: Drugs & Pharmacology Authors: Jenna C Stone Maureen J MacDonald Source Type: research
The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: A narrative review
Vascul Pharmacol. 2023 Aug 15;152:107209. doi: 10.1016/j.vph.2023.107209. Online ahead of print.ABSTRACTVascular endothelial and smooth muscle cell dysfunction proceed the development of numerous vascular diseases, such as atherosclerosis. Both estrogen and progesterone receptors are present on vascular endothelial and smooth muscle cells, and therefore it has been postulated that these compounds may affect vascular function. It has been well-established that estrogen is a vasoprotective compound, however, the effects of progesterone on vascular function are not well understood. This narrative review summarizes the current...
Source: Vascular Pharmacology - August 17, 2023 Category: Drugs & Pharmacology Authors: Jenna C Stone Maureen J MacDonald Source Type: research
The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: A narrative review
Vascul Pharmacol. 2023 Aug 15:107209. doi: 10.1016/j.vph.2023.107209. Online ahead of print.ABSTRACTVascular endothelial and smooth muscle cell dysfunction proceed the development of numerous vascular diseases, such as atherosclerosis. Both estrogen and progesterone receptors are present on vascular endothelial and smooth muscle cells, and therefore it has been postulated that these compounds may affect vascular function. It has been well-established that estrogen is a vasoprotective compound, however, the effects of progesterone on vascular function are not well understood. This narrative review summarizes the current res...
Source: Vascular Pharmacology - August 17, 2023 Category: Drugs & Pharmacology Authors: Jenna C Stone Maureen J MacDonald Source Type: research
The impacts of endogenous progesterone and exogenous progestin on vascular endothelial cell, and smooth muscle cell function: A narrative review
Vascul Pharmacol. 2023 Aug 15:107209. doi: 10.1016/j.vph.2023.107209. Online ahead of print.ABSTRACTVascular endothelial and smooth muscle cell dysfunction proceed the development of numerous vascular diseases, such as atherosclerosis. Both estrogen and progesterone receptors are present on vascular endothelial and smooth muscle cells, and therefore it has been postulated that these compounds may affect vascular function. It has been well-established that estrogen is a vasoprotective compound, however, the effects of progesterone on vascular function are not well understood. This narrative review summarizes the current res...
Source: Vascular Pharmacology - August 17, 2023 Category: Drugs & Pharmacology Authors: Jenna C Stone Maureen J MacDonald Source Type: research
Organ-specific model of simulated ischemia/reperfusion and hyperglycemia based on engineered heart tissue
Vascul Pharmacol. 2023 Aug 10:107208. doi: 10.1016/j.vph.2023.107208. Online ahead of print.ABSTRACTHere we aimed to establish an in vitro engineered heart tissue (EHT) co-morbidity mimicking model of ischemia-reperfusion injury and diabetes. EHTs were generated from primary neonatal rat cardiomyocytes. Hyperglycemic conditions or hyperosmolar controls were applied for one day to model acute hyperglycemia and for seven days to model chronic hyperglycemia. 120 min' simulated ischemia (SI) was followed by 120 min' reperfusion (R) and 1-day follow-up reperfusion (FR). Normoxic controls (N) were not subjected to SI/R. Half of ...
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: J P álóczi Á Paál J Pigler B Kiss A Rhoden Z V Varga P Ferdinandy T Eschenhagen A G örbe Source Type: research
Retraction notice to "Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis" [Vascular Pharmacology 113 (2019) 86-91]
Vascul Pharmacol. 2023 Jan 12:107142. doi: 10.1016/j.vph.2023.107142. Online ahead of print.NO ABSTRACTPMID:37573190 | DOI:10.1016/j.vph.2023.107142 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: Amr Shaaban Hanafy Sherief Abd-Elsalam Mohammed M Dawoud Source Type: research
Organ-specific model of simulated ischemia/reperfusion and hyperglycemia based on engineered heart tissue
Vascul Pharmacol. 2023 Aug 10:107208. doi: 10.1016/j.vph.2023.107208. Online ahead of print.ABSTRACTHere we aimed to establish an in vitro engineered heart tissue (EHT) co-morbidity mimicking model of ischemia-reperfusion injury and diabetes. EHTs were generated from primary neonatal rat cardiomyocytes. Hyperglycemic conditions or hyperosmolar controls were applied for one day to model acute hyperglycemia and for seven days to model chronic hyperglycemia. 120 min' simulated ischemia (SI) was followed by 120 min' reperfusion (R) and 1-day follow-up reperfusion (FR). Normoxic controls (N) were not subjected to SI/R. Half of ...
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: J P álóczi Á Paál J Pigler B Kiss A Rhoden Z V Varga P Ferdinandy T Eschenhagen A G örbe Source Type: research
Retraction notice to "Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis" [Vascular Pharmacology 113 (2019) 86-91]
Vascul Pharmacol. 2023 Jan 12:107142. doi: 10.1016/j.vph.2023.107142. Online ahead of print.NO ABSTRACTPMID:37573190 | DOI:10.1016/j.vph.2023.107142 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: Amr Shaaban Hanafy Sherief Abd-Elsalam Mohammed M Dawoud Source Type: research
Organ-specific model of simulated ischemia/reperfusion and hyperglycemia based on engineered heart tissue
Vascul Pharmacol. 2023 Aug 10:107208. doi: 10.1016/j.vph.2023.107208. Online ahead of print.ABSTRACTHere we aimed to establish an in vitro engineered heart tissue (EHT) co-morbidity mimicking model of ischemia-reperfusion injury and diabetes. EHTs were generated from primary neonatal rat cardiomyocytes. Hyperglycemic conditions or hyperosmolar controls were applied for one day to model acute hyperglycemia and for seven days to model chronic hyperglycemia. 120 min' simulated ischemia (SI) was followed by 120 min' reperfusion (R) and 1-day follow-up reperfusion (FR). Normoxic controls (N) were not subjected to SI/R. Half of ...
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: J P álóczi Á Paál J Pigler B Kiss A Rhoden Z V Varga P Ferdinandy T Eschenhagen A G örbe Source Type: research
